Core B - Experimental Glioma Animal Models Core This core facility will assist each Project Leader in this Program Project Grant to test, in relevant animal models of brain tumors, preclinical safety and efficacy of various therapies designed to achieve an improved anti-glioma effect The animal models we will employ are likely to identify both toxicity and efficacy of therapeutic modalities that might be advanced to treat patients with malignant brain tumors. This core will centralize animal experimentation associated with this Program, standardizing expert surgical and animal handling techniques and minimizing chances for trivial interferences that could hamper comparative analyses. Tumor volume, tumor mass and survival statistics will be collected where appropriate. Normal and tumor tissues will be collected and submitted to each investigator or will be processed in this core for gene expression or histopathologic analyses. Project 1 will require glioma xenografts in immunocompromised mice to determine the safety and efficacy of wild-type HSV-1 engineered to target human malignant glioma cells expressing unique receptor molecules. Hybridomas expressing anti-CDI 33 will be produced in the Core to acquire single chain antibody DNA. Project 2 will evaluate the capacity of a AYI34.5 HSV engineered to express activated MEK to facilitate HSV late gene expression in human glioma xenografts in the brains of nude mice. Project 3 will examine the susceptibility of human glioma progenitor cells in human glioma xenografts to genetically engineered HSV to define virus-host cell interactions and to characterize and improve HSV-mediated oncolysis of gliomas. Project 4 will characterize virus-host interactions in brain tumor tissues from a Phase I clinical trials with M032 (human IL-12 expressing). The Core will assist with development of animal brain tumor models to test findings from these correlative studies with human glioma specimens. Bioluminescence imaging to monitor glioma growth and response to therapy will be coordinated by the Core. The Core will assist with pre-IND safety studies in HSV-sensitive New-World owl monkeys (Aotus spp.) or marmosets (Callithrix spp) conducted to define any unanticipated toxicities to primate brain The Core will coordinate with the 8.5T/9.4T Small Animal NMR Facility for all NMR imaging studies of tumor- bearing mice involved in these preclinical evaluations and will coordinate with the 4.7T nonhuman primate NMR for imaging and spectroscopic studies. Finally, the Core will continue to evaluate serially passaged human glioma xenografts as well as specific transgenic models for preclinical toxicity and efficacy analyses for each ofthe unique genetically engineered HSV developed and/or characterized by Projects 1, 2 and 3.

Public Health Relevance

The EGAM Core is an essential component to the process of translating novel therapies from the laboratory to clinical application. Animal testing, performed in a highly standardized fashion by trained, skilled and experienced professionals, is a prerequisite for FDA approval to initiate-IRB approved clinical trials in humans. Moreover, our brain tumor models replicate, in most ways, the biology and physiology of high grade gliomas in patients and as such can be predictive of the likelihood of success or failure of novel therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA071933-11A1
Application #
7747240
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Project Start
2009-07-01
Project End
2014-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
11
Fiscal Year
2009
Total Cost
$180,240
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Waters, Alicia M; Johnston, James M; Reddy, Alyssa T et al. (2017) Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Hum Gene Ther Clin Dev 28:7-16
Ring, Eric K; Markert, James M; Gillespie, G Yancey et al. (2017) Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res 23:342-350
Foreman, Paul M; Friedman, Gregory K; Cassady, Kevin A et al. (2017) Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics 14:333-344
Ring, Eric K; Li, Rong; Moore, Blake P et al. (2017) Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Mol Ther Oncolytics 7:27-36
Patel, Daxa M; Foreman, Paul M; Nabors, L Burt et al. (2016) Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev 27:69-78
Friedman, Gregory K; Moore, Blake P; Nan, Li et al. (2016) Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18:227-35
McFarland, Braden C; Marks, Margaret P; Rowse, Amber L et al. (2016) Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma. Oncotarget 7:20621-35
Jackson, Joshua D; Markert, James M; Li, Li et al. (2016) STAT1 and NF-?B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res 14:482-92
Friedman, Gregory K; Beierle, Elizabeth A; Gillespie, George Yancey et al. (2015) Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2:

Showing the most recent 10 out of 172 publications